What does Utah Medical Products do?
Utah Medical Products, Inc. is a vertically integrated specialty medical-device manufacturer listed on Nasdaq as UTMD. It serves obstetrics, gynecology, neonatal intensive care, blood-pressure monitoring, electrosurgery and urology. Rather than selling large capital systems, UTMD concentrates on consumables, catheters, surgical tools and monitoring components used in procedures where reliability and clinical familiarity matter.
Which clinical product families define the company?
The portfolio includes BT-Cath balloon tamponade catheters, CVX-Ripe cervical-ripening catheters, vacuum-assisted delivery systems and fetal-monitoring accessories. Neonatal products cover drainage, feeding and vascular access, while gynecology products include electrodes, Filshie clips and applicators. The official labor-and-delivery portfolio illustrates UTMD’s narrow procedural focus.
Why does its global footprint matter?
Manufacturing is concentrated in Utah and Ireland, with commercial operations in England, Australia and Canada. This structure supports direct hospital relationships in selected markets and distributors elsewhere. The official corporate site emphasizes products for women and babies. International reach diversifies channels while adding currency and trade exposure.
How does Utah Medical Products make money?
UTMD records revenue when it ships finished devices, disposable accessories and components at agreed prices. Customers include hospitals, clinical facilities, distributors and OEM partners. OEM manufacturing uses the company’s molds, clean rooms, engineering and quality systems, helping absorb fixed factory costs even when orders are less predictable than direct hospital demand.
What are the principal revenue streams?
| Revenue stream | Customer and pricing logic | Economic characteristic |
|---|---|---|
| Direct specialty devices | Hospitals and clinical facilities; fixed product pricing, sometimes under annual volume agreements. | Recurring procedure demand, attractive margins and clinical differentiation. |
| Filshie Clip System | Direct U.S. and selected overseas facilities plus specialist distributors. | Established franchise with regulatory, litigation and geographic sensitivity. |
| OEM components and assemblies | Medical and selected non-medical device companies purchasing molded or assembled components. | Less predictable orders, but useful factory-overhead absorption. |
| International distribution | Subsidiaries and independent distributors outside the U.S. | Extends reach while adding currency and trade risk. |
How do customer relationships affect revenue quality?
Most clinical orders ship within days, so backlog mainly reflects larger OEM and distributor orders. Backlog due within 90 days was $0.731 million at January 1, 2026, versus $1.885 million a year earlier. The 2025 Form 10-K shows why mix matters: PendoTECH revenue peaked at $11.6 million in 2022 but fell to about $0.4 million in 2025.
Which products and geographies matter most?
Which product category generated the most revenue in 2025?
Gynecology, electrosurgery and urology generated $19.719 million, or 51% of fiscal 2025 revenue. Neonatal products produced $8.010 million, blood-pressure monitoring and accessories $6.793 million, and obstetrics $3.998 million. Filshie products alone represented 26% of sales, creating meaningful product concentration.
How balanced is the geographic mix?
Fiscal 2025 revenue was $22.761 million in the United States, $7.928 million in Europe and $7.831 million in other markets. Outside-U.S. sales were about 41% of total revenue, while foreign-currency invoices represented 30%. Exchange rates and local distribution therefore matter without displacing the U.S. as the core market.
The official Filshie product page explains the franchise, while filings show that distributor changes can materially alter quarterly comparisons.
What does Utah Medical Products’ latest quarter show?
For the quarter ended March 31, 2026, revenue fell because UTMD had no sales to its former China distributor and no continuing PendoTECH sensor shipments. Those relationships contributed $0.857 million in 1Q 2025 and explained 87% of the year-over-year decline. Domestic revenue was nearly flat; international sales weakened.
How did earnings compare with the prior year?
| Metric | 1Q 2026 | 1Q 2025 | Change | Interpretation |
|---|---|---|---|---|
| Net sales | $8.722M | $9.710M | Decline of 10.2% | Large-customer exits outweighed stable domestic totals. |
| Gross profit | $5.282M | $5.538M | Decline of 4.6% | Favorable mix limited the impact of lower volume. |
| Operating income | $2.565M | $3.154M | Decline of 18.7% | Higher G&A and litigation expense pressured operating leverage. |
| Net income | $2.604M | $3.041M | Decline of 14.4% | A lower tax rate softened the pretax decline. |
| Diluted EPS | $0.818 | $0.919 | Decline of 11.0% | Repurchases reduced the diluted share count and supported EPS. |
Why did gross margin rise while operating margin fell?
The 1Q 2026 Form 10-Q reported $5.560 million of domestic sales and $3.162 million outside the U.S. Gynecology, electrosurgery and urology supplied 60% of quarterly revenue, supporting gross margin despite lower volume.
What strategic turning points shaped Utah Medical Products?
UTMD evolved through focused product and manufacturing additions rather than repeated transformational mergers. It raised public equity once, in 1982, then relied on internal cash generation. Acquisitions expanded neonatal, fetal-monitoring and female-sterilization capabilities, while direct distribution increased control over customers.
Which events still influence today’s model?
-
1978UTMD formed in Utah, establishing today’s specialty-device core.
-
1982The company completed its only public stock sale, raising $1.750 million before offering costs; subsequent growth was largely self-funded.
-
1997–1998Columbia Medical and Gesco acquisitions added products that remain part of the portfolio, including neonatal and specialty-care lines.
-
2004The Abcorp acquisition internalized a supplier of fetal-monitoring belts, while the company began the long-running pattern of quarterly cash dividends.
-
2011UTMD acquired Femcare, adding the Filshie Clip System and distribution operations in the UK and Australia.
-
2019UTMD became the exclusive U.S. distributor to medical facilities for Filshie devices, gaining greater control of domestic pricing and customer access.
-
2024–2025Aggressive share repurchases reduced outstanding shares while revenue from PendoTECH and the China distributor declined.
-
2026Management is pursuing direct high-pressure biopharma sensor sales, international recovery and completion of Femcare acquisition amortization.
Why was the Femcare acquisition decisive?
Femcare added the Filshie franchise, overseas infrastructure and substantial intangible assets. The 2011 acquisition announcement identified Filshie as its leading brand. Related amortization exceeded $2 million annually before largely ending in 1Q 2026, so analysts should distinguish business improvement from the mechanical expense decline.
What gives Utah Medical Products a competitive advantage?
How do quality systems and regulation create barriers?
Medical-device production requires validated processes, traceability, design controls and regulatory clearance. UTMD’s Utah, Ireland and UK facilities are certified under ISO 13485:2016 and participate in the Medical Device Single Audit Program. The Ireland facility’s 2024 FDA inspection produced no FDA-483 observations. Filshie is a Class III device; most other products are unclassified, Class I or Class II. This infrastructure raises entry costs.
Why can small niche products still support a moat?
UTMD competes through procedure-specific design, reliability and clinical familiarity rather than lowest price. BT-Cath, neonatal catheters and Filshie clips are used where failure can be consequential. Seven unexpired U.S. patents provide some protection, but the broader moat combines decades of use, quality-system credibility, direct relationships and the inconvenience of qualifying alternatives.
Who does UTMD compete against?
| Competitive group | Where pressure appears | UTMD response |
|---|---|---|
| Diversified med-tech suppliers | Broader contracts, purchasing leverage and global coverage. | Differentiate through focused products and specialist support. |
| Single-product specialty firms | Competition within a catheter, electrode or surgical niche. | Clinical history, reliability and established approvals. |
| Low-cost OEM manufacturers | Lower-cost regions can undercut labor expense. | Certified quality, engineering support and small-batch flexibility. |
| Alternative procedures or devices | Clinicians may select an alternative procedure. | Demonstrate safety, usability, cost and outcomes. |
How financially strong is Utah Medical Products?
At March 31, 2026, UTMD held $87.406 million of cash, $124.382 million of assets, $4.009 million of liabilities and $120.373 million of equity, with no debt. Cash represented roughly 70% of assets, creating unusual flexibility for a company with quarterly revenue below $10 million.
What do profitability and cash conversion show?
Fiscal 2025 revenue was $38.520 million, gross profit $22.001 million, operating income $11.402 million and net income $11.286 million. Operating cash flow of $14.692 million less $0.371 million of capital spending produced about $14.321 million of simple free cash flow.
How does management allocate capital?
| Capital-allocation item | FY2025 amount | Interpretation |
|---|---|---|
| Cash dividends | $3.983M | Continues a quarterly dividend practice maintained since 2004. |
| Share repurchases | $8.355M | 148,935 shares bought at an average $56.10 per share. |
| Capital expenditures | $0.371M | Low maintenance and expansion needs relative to cash generation. |
| R&D expense | $0.668M | Focused product development rather than a large research platform. |
| Debt repayment | $0 | No borrowings were outstanding or required. |
When attractive reinvestment is limited, UTMD returns cash through dividends and repurchases. Its annual reports and proxy materials document that policy.
Who owns Utah Medical Products stock, and how is it governed?
UTMD has one common share class and no dual-class controller. Its investor base combines active, quantitative and passive institutions with meaningful management ownership, but no disclosed holder has majority voting power.
Which holders have the largest disclosed stakes?
| Holder or group | Shares | Ownership | Why it matters |
|---|---|---|---|
| Brandes Investment Partners | 351,322 | 11.0% | Largest disclosed holder; can scrutinize valuation and capital allocation. |
| Dimensional Fund Advisors | 196,509 | 6.2% | Systematic ownership supports liquidity but can shift with factors. |
| Renaissance Technologies | 193,614 | 6.1% | Quantitative block within a small share base. |
| BlackRock | 184,537 | 5.8% | Voting policies matter in director and compensation votes. |
| Vanguard | 175,971 | 5.5% | Large institution without operating control. |
| Directors and executive officers as a group | 254,216 | 8.0% | Meaningful alignment, but no majority control. |
What governance features should researchers notice?
The 2026 proxy reported a roughly 1:8 CEO pay ratio: $341,709 of 2025 CEO compensation versus about $43,500 for the median employee. Incentives emphasize pretax earnings, reinforcing a profitability-focused culture. The governance page provides committee and policy materials.
What opportunities could improve Utah Medical Products’ growth?
Where can replacement revenue come from?
The immediate growth task is replacing PendoTECH and former China-distributor revenue. Management is selling high-pressure process-control transducers directly to biopharmaceutical manufacturers, reducing reliance on one OEM intermediary. Additional paths include stronger overseas Filshie demand, new clinician-focused devices and an accretive product-line or company acquisition funded by the cash balance.
How could operating leverage improve?
UTMD’s fixed manufacturing base is lightly capital intensive; fiscal 2025 net property and equipment turned 3.9 times. Incremental revenue can therefore improve overhead absorption. Completion of Femcare amortization should also reduce 2026 G&A expense by about $1.6 million versus 2025, although analysts should treat this as a discrete accounting tailwind.
What risks could weaken Utah Medical Products’ outlook?
Which operating risks are most material?
The main risk is concentration rather than leverage. PendoTECH and China-distributor declines show how quickly revenue can reset. UTMD also self-insures product liability and faces Filshie litigation. Litigation expense was $1.355 million in fiscal 2025 and $0.441 million in 1Q 2026. Even without an adverse judgment, defense costs can pressure margins.
What financial lines reveal rising pressure?
Operating expense intensity is the clearest pressure signal. In 1Q 2026, operating expenses were 31.1% of revenue versus 24.6% in 1Q 2025. Lower volume can coexist with a high gross margin while G&A, litigation and compliance absorb the benefit. Safety-stock inventory protects supply but raises obsolescence risk if demand slows. The SEC filing history allows period-by-period tracking.
Which KPIs and valuation drivers matter most for UTMD?
What should be monitored each quarter?
| KPI or driver | Current reference point | How to interpret it |
|---|---|---|
| Organic direct-device revenue | Domestic total was $5.560M in 1Q 2026 | Separates core hospital demand from lost external business. |
| Gynecology/electrosurgery/urology mix | 60% of 1Q 2026 revenue | Supports gross margin but increases Filshie dependence. |
| Gross margin | 60.6% in 1Q 2026 | Shows mix, pricing, efficiency and tariff effects. |
| Operating margin | 29.4% in 1Q 2026 | Tests whether overhead offsets gross-margin strength. |
| Free-cash-flow conversion | Approx. $2.979M in 1Q 2026 | $3.109M operating cash flow less $0.130M capex, versus $2.604M net income. |
| Share count | 3.184M shares at March 31, 2026 | Shows whether buybacks offset earnings pressure. |
| Cash deployment | $87.406M cash at March 31, 2026 | Funds acquisitions or returns; idle cash lowers asset productivity. |
How should UTMD be approached in a DCF?
A DCF should value the operating business and excess cash separately. Revenue assumptions should distinguish replacement of lost PendoTECH and China-distributor sales from underlying direct-device growth. Gross margin depends on product mix; operating margin should normalize Femcare amortization and litigation. Reinvestment is low unless acquisitions alter the profile. Terminal assumptions should reflect small scale, product concentration, regulation and succession risk.
What is the key takeaway from Utah Medical Products analysis?
UTMD is a small, highly profitable and lightly capital-intensive medical-device company with an exceptional cash position. Its strongest assets are focused clinical products, established manufacturing and regulatory systems, direct relationships in selected markets and disciplined capital allocation. These qualities support durable margins, but they do not guarantee growth.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.